Multi-Centre Based Study Recognition of Atrial Fibrillation With the Corsano CardioWatch 287-2 System
Launched by CORSANO HEALTH B.V. · Apr 30, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a wristband device called the Corsano CardioWatch 287-2, which monitors heart rhythms to help detect a condition known as atrial fibrillation (AF). Atrial fibrillation is a type of irregular heartbeat that can lead to serious health issues. The trial aims to see how well this wristband works at identifying AF compared to traditional heart monitoring methods like a 12-lead ECG or a 24-hour Holter monitor. Researchers will involve patients in different groups, including those who are already being monitored for heart issues and those who have been diagnosed with AF.
To be eligible for this study, participants need to be at least 22 years old and should have symptoms related to heart rhythm problems or a previous diagnosis of arrhythmia. They must also be comfortable communicating in Dutch or English. Participants can expect to wear the wristband while continuing their usual activities, and the study will help determine how effective this new technology is in real-life situations. It’s important to note that the trial is not yet recruiting participants, and safety is a priority, so some individuals may not be able to participate based on their health conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with symptoms indicative of cardiac arrhythmias receiving 24-48 hour ECG holter for home monitoring or in-clinic 12-lead ECG per doctor prescription OR previous diagnosis of arrhythmia presenting to the clinic for routine follow-up evaluation
- • Age ≥ 22 years old
- • Able to provide informed consent.
- • Proficient in written and spoken Dutch or English, defined by self-report of comfort reading, writing, and speaking Dutch or English.
- Exclusion Criteria:
- • Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol;
- • Unable to wear the Corsano CardioWatch 287 due to reasons such as allergic reactions, wounds, amputations etc.;
- • Unable or not willing to receive ECG monitoring;
- • Unable or not willing to sign informed consent;
About Corsano Health B.V.
Corsano Health B.V. is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and development. Specializing in the design and execution of clinical studies, Corsano Health leverages cutting-edge technologies and methodologies to enhance patient outcomes and drive efficiencies in the clinical trial process. With a commitment to ethical practices and regulatory compliance, the organization collaborates with various stakeholders, including healthcare professionals, research institutions, and biopharmaceutical companies, to bring transformative therapies to market. Corsano Health B.V. is at the forefront of improving clinical trial strategies, ultimately contributing to the evolution of personalized medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Delft, Zuid Holland, Netherlands
Patients applied
Trial Officials
Eelko Ronner, MD, PhD
Principal Investigator
Reinier de Graaf Groep
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported